The Anti-IL-13 Reference Antibody (dectrekumab) is a recombinant monoclonal antibody used primarily as a reference standard in clinical research and development for evaluating novel anti-IL-13 therapies. It targets and neutralizes interleukin-13 (IL-13), a key cytokine in type 2 inflammation pathways, which are implicated in conditions such as moderate to severe asthma (especially with elevated eosinophils or high FeNO), atopic dermatitis, and chronic rhinosinusitis with nasal polyps. By blocking IL-13, dectrekumab was investigated in clinical trials to reduce asthma exacerbations, improve lung function, and minimize oral corticosteroid dependence through inhibition of airway inflammation, mucus hypersecretion, and bronchial hyperresponsiveness. As a research tool, it enables precise comparison of efficacy, specificity, and biological properties of new antibody candidates in bioassays, quality control, and drug development pipelines.